Metabolic Technologies is known for its discovery of beta-hydroxy-beta-methylbutyrate (HMB) – a metabolite of the amino acid leucine – in the early 1990s.
Since, HMB has been popular among sports nutrition brands in the form of bars, RTD beverages and supplements to support strength, recovery and improved body composition for competitive athletes.
In addition, a growing body of scientific research suggests that HMB has muscle health benefits that may serve a larger base of consumers beyond traditional sports nutrition.
TSI will communicate these benefits through the awareness and education growth strategy behind its branded ingredient, myHMB.
Metabolic Technologies chief operating officer Shawn Baier said: “myHMB is a well-proven muscle health ingredient that benefits consumers through a dual mechanism that builds muscle mass and strength while preserving muscle as you age.
“myHMB is supported by hundreds of clinical trials with unparalleled safety and efficacy data, all tied to TSI’s proprietary, world-class manufacturing process. Muscle loss impacts everyone as they age and it plays a crucial role in boosting consumers’ muscle health and quality of life,” he explained.
TSI USA president Larry Kolb commented: “This acquisition allows us to drastically expand our global market reach and access through globally aligned technical and commercial teams.
“We are implementing an aggressive plan that expands myHMB market awareness and education with key brand partners who are highly motivated to take advantage of this untapped growth opportunity.
“Musculoskeletal joint and bone health categories are mature, multi-billion-dollar categories for food and supplement brands, while the muscle health category remains in its infancy. Muscle health awareness and its importance is just now starting to emerge, especially for the ageing population,” he said.
© FoodBev Media Ltd 2020